Natera's Prospera test can assess kidney transplant-related disease severity as well as rejection risk in patients hospitalized with COVID-19, according to research published on March 15 in Transplantation Proceedings.
The company said results from its Prospera test show that high levels of total cell-free DNA (cfDNA), which can occur due to COVID-19 infection, lead to a lower donor-derived-cfDNA donor fraction. This means it can inadvertently mask rejection when using donor fraction alone.
The company also highlighted that the test identified two patients in the cohort with elevated total cfDNA and biopsy-proven rejection that would have otherwise gone undetected by donor fraction alone.
